Table 2.
Responsiveness to treatment with dopamine agonists in patients with prolactinomas in the context of a multiple endocrine neoplasia type 1
| Author, year (reference) | Patients | Prolactinomas (%) | Micro | Macro | Dopamine agonist responders (%) |
|---|---|---|---|---|---|
| Burgess, 1996 (24) | 165 | 18a | 7 | 5 | 7 (58.3)b |
| Verges, 2002 (25) | 324 | 84 (26) | 13 | 71 | 35 (42) |
| de Laat, 2015 (26) | 323 | 50 (15.5) | 30 | 20 | 31 (59.6) |
| Goroshi, 2016 (27) | 18 | 8 (44.4) | 3 | 5 | 8 (100) |
| Vannucci, 2017 (28) | 22 | 7 (31.8) | 5 | 2 | 5 (71.4) |
| Total | 852 | 167 (19.6) | 58 (34.7) | 103 (61.7) | 86 (51.5) |
Six patients with normal pituitary scan.
Calculated on 12 patients with tumor evidence at pituitary scan.